New HQ in Stockholm for Modus Therapeutics
Modus Therapeutics AB, a Karolinska Development (STO:KDEV) portfolio company focused on innovative treatments for patients with sickle-cell disease, is set to move headquarters in the coming month.
Currently based at the Karolinska Insitute Science Park in Solna, Stockholm, Modus Therapeutics is to move into workspace more suitable for its business in the centre of Stockholm. The move comes at a key time for the company as it looks to enroll the first patient in its forthcoming Phase II study with sevuparin in patients with Sickle-Cell Disease.
CEO Christina Herder said: “We are extremely pleased to be moving our operation, especially at this time of exciting progress for Modus Therapeutics. Our new office in Stockholm will give us the set-up and flexibility to further develop and expand our operation as we continue in our work to develop our lead candidate sevuparin.”